Carcinoid Syndrome Diarrhea Archives

Ipsen Receives Approval from European Commission for Xermelo for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy

Approvals, Biopharma, Carcinoid Syndrome, Carcinoid Syndrome Diarrhea, European Commission, First-In-Class, Tryptophan Hydroxylase Inhibitors

Ipsen today announced that the European Commission approved Xermelo (telotristat ethyl) 250 mg three times a day for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.

September 19, 2017/by Business Wire